OptimizeRx Statistics
Total Valuation
OptimizeRx has a market cap or net worth of $123.08 million. The enterprise value is $125.82 million.
| Market Cap | 123.08M |
| Enterprise Value | 125.82M |
Important Dates
The next estimated earnings date is Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OptimizeRx has 18.76 million shares outstanding. The number of shares has increased by 3.86% in one year.
| Current Share Class | 18.76M |
| Shares Outstanding | 18.76M |
| Shares Change (YoY) | +3.86% |
| Shares Change (QoQ) | -0.41% |
| Owned by Insiders (%) | 14.80% |
| Owned by Institutions (%) | 67.81% |
| Float | 14.48M |
Valuation Ratios
The trailing PE ratio is 24.30 and the forward PE ratio is 6.79.
| PE Ratio | 24.30 |
| Forward PE | 6.79 |
| PS Ratio | 1.12 |
| Forward PS | 1.08 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 7.40 |
| P/FCF Ratio | 6.60 |
| P/OCF Ratio | 6.58 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.68, with an EV/FCF ratio of 6.74.
| EV / Earnings | 24.52 |
| EV / Sales | 1.15 |
| EV / EBITDA | 7.68 |
| EV / EBIT | 10.43 |
| EV / FCF | 6.74 |
Financial Position
The company has a current ratio of 3.04, with a Debt / Equity ratio of 0.20.
| Current Ratio | 3.04 |
| Quick Ratio | 2.91 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 1.57 |
| Debt / FCF | 1.40 |
| Interest Coverage | 2.28 |
Financial Efficiency
Return on equity (ROE) is 4.18% and return on invested capital (ROIC) is 6.79%.
| Return on Equity (ROE) | 4.18% |
| Return on Assets (ROA) | 4.33% |
| Return on Invested Capital (ROIC) | 6.79% |
| Return on Capital Employed (ROCE) | 7.75% |
| Weighted Average Cost of Capital (WACC) | 11.94% |
| Revenue Per Employee | $822,774 |
| Profits Per Employee | $38,586 |
| Employee Count | 133 |
| Asset Turnover | 0.63 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, OptimizeRx has paid $1.82 million in taxes.
| Income Tax | 1.82M |
| Effective Tax Rate | 26.16% |
Stock Price Statistics
The stock price has decreased by -19.80% in the last 52 weeks. The beta is 1.28, so OptimizeRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -19.80% |
| 50-Day Moving Average | 8.25 |
| 200-Day Moving Average | 13.80 |
| Relative Strength Index (RSI) | 42.57 |
| Average Volume (20 Days) | 601,145 |
Short Selling Information
The latest short interest is 1.59 million, so 8.48% of the outstanding shares have been sold short.
| Short Interest | 1.59M |
| Short Previous Month | 1.40M |
| Short % of Shares Out | 8.48% |
| Short % of Float | 10.99% |
| Short Ratio (days to cover) | 3.27 |
Income Statement
In the last 12 months, OptimizeRx had revenue of $109.43 million and earned $5.13 million in profits. Earnings per share was $0.27.
| Revenue | 109.43M |
| Gross Profit | 73.60M |
| Operating Income | 12.06M |
| Pretax Income | 6.95M |
| Net Income | 5.13M |
| EBITDA | 16.39M |
| EBIT | 12.06M |
| Earnings Per Share (EPS) | $0.27 |
Balance Sheet
The company has $23.37 million in cash and $26.10 million in debt, with a net cash position of -$2.74 million or -$0.15 per share.
| Cash & Cash Equivalents | 23.37M |
| Total Debt | 26.10M |
| Net Cash | -2.74M |
| Net Cash Per Share | -$0.15 |
| Equity (Book Value) | 128.29M |
| Book Value Per Share | 6.84 |
| Working Capital | 43.45M |
Cash Flow
In the last 12 months, operating cash flow was $18.72 million and capital expenditures -$58,000, giving a free cash flow of $18.66 million.
| Operating Cash Flow | 18.72M |
| Capital Expenditures | -58,000 |
| Depreciation & Amortization | 4.33M |
| Net Borrowing | -8.00M |
| Free Cash Flow | 18.66M |
| FCF Per Share | $0.99 |
Margins
Gross margin is 67.25%, with operating and profit margins of 11.02% and 4.69%.
| Gross Margin | 67.25% |
| Operating Margin | 11.02% |
| Pretax Margin | 6.35% |
| Profit Margin | 4.69% |
| EBITDA Margin | 14.98% |
| EBIT Margin | 11.02% |
| FCF Margin | 17.05% |
Dividends & Yields
OptimizeRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.86% |
| Shareholder Yield | -3.86% |
| Earnings Yield | 4.17% |
| FCF Yield | 15.16% |
Analyst Forecast
The average price target for OptimizeRx is $16.67, which is 154.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.67 |
| Price Target Difference | 154.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 14, 2018. It was a reverse split with a ratio of 1:3.
| Last Split Date | May 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:3 |
Scores
OptimizeRx has an Altman Z-Score of 3.35 and a Piotroski F-Score of 8.
| Altman Z-Score | 3.35 |
| Piotroski F-Score | 8 |